Peginterferon alpha versus other antiviral regimes for Chinese HBeAg-positive chronic hepatitis B patients.
10.3969/j.issn.1672-7347.2013.12.001
- Author:
Zhenzhen DENG
1
;
Chunjiang WANG
;
Zuojun LI
;
Bing LI
;
Shikun LIU
Author Information
1. Department of Pharmacy, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- MeSH:
Adenine;
analogs & derivatives;
therapeutic use;
Antiviral Agents;
therapeutic use;
China;
Drug Therapy, Combination;
Guanine;
analogs & derivatives;
therapeutic use;
Hepatitis B Surface Antigens;
Hepatitis B e Antigens;
Hepatitis B, Chronic;
drug therapy;
Humans;
Interferon-alpha;
therapeutic use;
Organophosphonates;
therapeutic use;
Polyethylene Glycols
- From:
Journal of Central South University(Medical Sciences)
2013;38(12):1193-1207
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To conduct a meta-analysis to determine the efficacy of peginterferon alpha (PEG-IFN α) therapy versus IFN α, adefovir dipivoxil (ADV) and entecavir (ETV) for HBeAg-positive chronic hepatitis B patients in China.
METHODS:MEDLINE database and 3 main Chinese biomedical databases between 1966 and 2012 was retrieved. Two reviewers independently screened all reports to identify randomized controlled trials that evaluated PEG-IFN α therapy for the treatment of chronic hepatitis B in China.
RESULTS:Fourteen trials met the eligibility criteria for this Meta analysis. PEG-IFN α therapy was more effective than IFN α therapy in achieving ALT normalization, serum HBV DNA clearance, HBeAg seroconversion, serum HBeAg clearance and fibrosis improvement in Chinese hepatitis B patients (P<0.05). PEG-IFN α was obviously superior to ETV in HBeAg seroconversion and serum HBeAg clearance (P<0.05), but the seroconversion rate was low. The combination therapy of PEG-IFN α and ADV was more effective than ADV monotherapy in ALT normalization, serum HBV DNA clearance and HBeAg seroconversion (P<0.05). PEG-IFN α showed no priority to other treatment regimes in HBsAg clearance.
CONCLUSION:Treatment with PEG-IFN α is safe and effective, and can be prescribed as firstline treatment options for chronic hepatitis B patients in China. Data are too limited to exclude a substantial benefit or harm of PEG-IFN α combination therapy for CHB patients in China.
